eFFECTOR Therapeutics (NASDAQ:EFTR) Earns Buy Rating from HC Wainwright

eFFECTOR Therapeutics (NASDAQ:EFTR)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $24.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 78.44% from the company’s current price.

eFFECTOR Therapeutics Stock Performance

Shares of eFFECTOR Therapeutics stock opened at $13.45 on Thursday. eFFECTOR Therapeutics has a 1 year low of $8.44 and a 1 year high of $37.00. The company has a market capitalization of $34.70 million, a P/E ratio of -0.79 and a beta of 0.52. The company’s fifty day moving average is $11.91 and its two-hundred day moving average is $12.81.

Institutional Trading of eFFECTOR Therapeutics

Several hedge funds have recently made changes to their positions in EFTR. State Street Corp acquired a new stake in shares of eFFECTOR Therapeutics in the 1st quarter worth $68,000. Renaissance Technologies LLC acquired a new stake in shares of eFFECTOR Therapeutics in the second quarter valued at about $42,000. Two Sigma Investments LP acquired a new stake in shares of eFFECTOR Therapeutics in the third quarter valued at about $27,000. CI Private Wealth LLC acquired a new stake in shares of eFFECTOR Therapeutics in the fourth quarter valued at about $118,000. Finally, Sea Otter Advisors LLC acquired a new stake in shares of eFFECTOR Therapeutics in the first quarter valued at about $93,000. Institutional investors and hedge funds own 57.67% of the company’s stock.

eFFECTOR Therapeutics Company Profile

eFFECTOR Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.